Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 11

Antiaging efficacy of melatonin-based day and night creams: a randomized, split-face, assessor-blinded proof-of-concept trial

Authors Milani M, Sparavigna A

Received 12 October 2017

Accepted for publication 29 December 2017

Published 24 January 2018 Volume 2018:11 Pages 51—57


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg

Massimo Milani,1 Adele Sparavigna2

1Medical Department, Cantabria Labs Difa Cooper, Caronno Pertusella, 2Derming, Clinical Research and Bioengineering Institute, Milan, Italy

Background: Skin is a complete and independent melatoninergic system. At the skin level, melatonin (Mel) acts as a relevant antioxidant and cytoprotective substance. Topical application of Mel is considered meaningful, since it can easily penetrate the stratum corneum. Exogenous Mel can be expected to represent a potent antioxidative defense system against skin aging mechanisms. Day and night creams containing Mel, carried in lipospheres (Melatosphere™), have been developed (Nutriage SPF 30 day cream and Nutriage night cream).
Study aim: The aim of this study was to evaluate the efficacy of a Mel-based cream as antiaging treatment.
Subjects and methods: In a randomized, split-face, assessor-blinded, prospective 3-month study, 22 women (mean age 55 years) with moderate–severe skin aging were enrolled (clinical trial registration number: NCT03276897). Study products were applied in the morning (Nutriage day cream) and evening (Nutriage night cream) on the right or left side of the face. Primary outcomes were: 1) clinical evaluation of wrinkles’ grade (crow’s feet and nasolabial folds), surface microrelief, skin tonicity (resistance to pinching and traction, recovery after pinching) and skin dryness and 2) instrumental evaluation of skin roughness and 3D photographic documentation (Vectra H1 images system). Assessments of both clinical and instrumental evaluations were performed at baseline and after 1, 2 and 3 months of treatment by an investigator unaware of treatment allocation.
Results: All the subjects completed the study. Crow’s feet was reduced significantly (p=0.05) by –15% with the creams in comparison with the non-treated side after 3 months. At the end of the study, surface microrelief (–26.5%), skin profilometry (–13%), skin tonicity (+30%) and skin dryness (–59.5%) significantly improved with active treatment. Both products were well tolerated.
Conclusion: In women with skin aging, Mel-based creams improved significantly skin tonicity and skin hydration with a significant reduction in skin roughness, supporting the skin antiaging effect of this molecule applied topically.

Keywords: melatonin, skin aging, assessor-blinded trial

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]